Patient-reported outcomes 1 year after oesophageal cancer surgery.

Acta Oncol

Department of Molecular Medicine and Surgery, Division of Surgical Care Science, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Published: June 2020

To improve survivorship in patients who have undergone curatively intended treatment for oesophageal cancer, we aimed to identify key targets for future patient-reported outcomes research. This nationwide Swedish prospective cohort study enrolled patients between 2014 and 2019 who had undergone surgical resection for oesophageal cancer 1 year earlier. Eight well-validated patient-reported outcome measures, including health-related quality of life, psychological status and sleep, were presented as proportions and mean scores (MS) with 95% confidence intervals (CIs). Among 281 participants, approximately half of the patients reported problems associated with food intake such as eating restrictions (49%) and food aversion (47%). Other common problems were sleep (51%), fatigue (41%) and anxiety (36%). Fewer patients suffered from financial difficulties (9%), trouble swallowing saliva (4%) and hair loss (7%). However, these problems were perceived as highly burdensome on an individual level. This nationwide, population-based study indicates that symptom burden is high in oesophageal cancer survivors 1 year after surgery. The most common problems are associated with food intake, sleep, fatigue and anxiety. However, less frequent symptoms were sometimes more debilitating for the individual patient.

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1741677DOI Listing

Publication Analysis

Top Keywords

oesophageal cancer
16
patient-reported outcomes
8
problems associated
8
associated food
8
food intake
8
common problems
8
outcomes year
4
oesophageal
4
year oesophageal
4
cancer
4

Similar Publications

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.

Int J Cancer

January 2025

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.

The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948).

View Article and Find Full Text PDF

Rechallenge with immune checkpoint inhibitors (ICI) shows promise in various cancers, but data in esophageal squamous cell carcinoma (ESCC) is limited. This study aimed to evaluate the efficiency and safety of ICI rechallenge in ESCC. This multicenter study analyzed ESCC patients rechallenged with ICI from January 2020 to March 2023 across two medical institutions.

View Article and Find Full Text PDF

Hypercalcemia is an identified complication of several malignancies and can cause significant adverse events. It is usually associated with cancers of the breast, lung (especially squamous cell), renal cell carcinoma, and multiple myeloma. Here, we present a rare case of esophageal adenocarcinoma presenting with hypercalcemia.

View Article and Find Full Text PDF

Objective: The advent of video-assisted thoracoscopic surgery in Mongolia has faced funding and accessibility challenges, leading to languid adoption. A Mongolian-Canadian collaboration was inaugurated to support the development of a self-sustainable, self-governed minimally invasive thoracic surgery (MITS) program in Mongolia.

Methods: A multidisciplinary Canadian thoracic surgery team collaborated with the National Cancer Center of Mongolia Thoracic Surgery service from 2016 to 2023.

View Article and Find Full Text PDF

Background: The wound healing effects of a specialized amino acid supplement containing calcium beta-hydroxy-beta-methylbutyrate, L-arginine, and L-glutamine (HMB/Arg/Gln) have been reported. This study aimed to investigate the effectiveness of HMB/Arg/Gln in the perioperative management of patients with thoracic esophageal cancer.

Methods: This retrospective cohort study included 131 patients who underwent esophagectomy for thoracic esophageal cancer between January 2016 and November 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!